SV2003000753A - Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico - Google Patents

Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico

Info

Publication number
SV2003000753A
SV2003000753A SV2001000753A SV2001000753A SV2003000753A SV 2003000753 A SV2003000753 A SV 2003000753A SV 2001000753 A SV2001000753 A SV 2001000753A SV 2001000753 A SV2001000753 A SV 2001000753A SV 2003000753 A SV2003000753 A SV 2003000753A
Authority
SV
El Salvador
Prior art keywords
polysacarids
zwitterionic
specific modulation
immune
progress
Prior art date
Application number
SV2001000753A
Other languages
English (en)
Inventor
Yin Wang
Michael H Roehrlt
Denis L Kasper
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of SV2003000753A publication Critical patent/SV2003000753A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)

Abstract

EL INVENTO SE RELACIONA CON UNA DETERMINACION DE LA ESTRUCTURA MOLECULAR TRIDIMENCIONAL DE POLIMEROS, MODELO MOLECULAR DE COMPUTADORA TRIDIMENSIONAL, DISEÑO DE FARMACO RACIONAL Y POLIMEROS INMUNOMODULADORES. EN PARTICULAR, EL INVENTO SE DIRIGE CON LOS POLIMEROS INMUNOMODULADORES, ASI COMO CON LOS METODOS PARA DISEÑAR, SELECCIONAR, Y TAMIZAR LOS AGENTES TERAPEUTICOS CON ACTIVIDAD INMUNOMODULADORA
SV2001000753A 2000-12-05 2001-11-30 Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico SV2003000753A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25174700P 2000-12-05 2000-12-05

Publications (1)

Publication Number Publication Date
SV2003000753A true SV2003000753A (es) 2003-06-16

Family

ID=22953235

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000753A SV2003000753A (es) 2000-12-05 2001-11-30 Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico

Country Status (9)

Country Link
US (2) US7629330B2 (es)
EP (1) EP1365774A2 (es)
JP (2) JP4431311B2 (es)
AR (1) AR036984A1 (es)
AU (1) AU2002228890A1 (es)
CA (1) CA2436666C (es)
PE (1) PE20020783A1 (es)
SV (1) SV2003000753A (es)
WO (1) WO2002045708A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
DK1261254T3 (da) * 2000-02-17 2010-01-04 Garnett Inc Fremgangsmåde til kontrol af vækst af akvatiske planter og zoologiske organismer
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
AU2003218144B2 (en) * 2002-03-13 2008-08-14 The Brigham And Women's Hospital, Inc. Method for overexpression of zwitterionic polysaccharides
EP1638581A2 (en) 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US6970791B1 (en) * 2003-05-23 2005-11-29 Verachem, Llc Tailored user interfaces for molecular modeling
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
WO2007023386A2 (en) * 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
US20110002965A1 (en) * 2007-11-09 2011-01-06 Round June L Immunomodulating compounds and related compositions and methods
EP2217250A4 (en) * 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
US20100275282A1 (en) * 2009-04-23 2010-10-28 Round June L Methods and systems for identifying immunomodulatory substances
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
EP2555753B1 (en) * 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
WO2013080561A1 (en) 2011-12-01 2013-06-06 University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
KR102473378B1 (ko) * 2017-08-31 2022-12-01 엘지디스플레이 주식회사 유기 발광 표시 장치
CN111171114B (zh) * 2020-01-17 2022-08-12 遵义医科大学 一种膦酸酯二肽类化合物及其应用
CN113327649B (zh) * 2021-06-30 2023-06-16 青岛科技大学 一种基于分子动力学的半纤维素溶解机理的分析方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS56128721A (en) 1980-03-12 1981-10-08 Eisai Co Ltd Antiallergic agent
SE456346B (sv) 1984-07-23 1988-09-26 Pharmacia Ab Gel for att forhindra adhesion mellan kroppsvevnader och sett for dess framstellning
US4619995A (en) 1984-12-24 1986-10-28 Nova Chem Limited N,O-carboxymethyl chitosan and preparative method therefor
ATE118784T1 (de) 1985-07-12 1995-03-15 Univ New York Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen.
US4684727A (en) 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
US4819617A (en) 1986-09-04 1989-04-11 University Of Florida Viscoelastic material for ophthalmic surgery
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
DE3704389A1 (de) 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung von lymphokinen durch induktion lymphoider zellen
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5140016A (en) 1988-05-31 1992-08-18 University Of Florida Method and composition for preventing surgical adhesions using a dilute solution of polymer
US5126141A (en) 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5196510A (en) 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5158939A (en) 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
KR0158436B1 (ko) 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5130417A (en) 1990-04-30 1992-07-14 Washington University Entamoeba histolytical immunogenic protein and cdna clone
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
GB2286193A (en) 1991-03-28 1995-08-09 Italfarmaco Spa Anticoagulants and processes for preparing such
GR920100122A (el) 1991-04-05 1993-03-16 Ethicon Inc Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5705178A (en) 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
DE69330464T2 (de) * 1992-09-24 2001-11-08 Brigham And Women S Hospital B Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
EP0740708B1 (en) * 1993-11-26 2004-08-04 Lawrence B. Hendry Design of drugs involving receptor-ligand-dna interactions
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5700787A (en) 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
AU697465B2 (en) * 1994-11-02 1998-10-08 Research Foundation Of The State University Of New York, The Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5679658A (en) 1995-05-08 1997-10-21 Chitogenics, Inc. N,O-carbonxymethylchitosan for prevention of surgical adhesions
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
CA2328436C (en) 1998-04-13 2008-08-05 Massachusetts Institute Of Technology Comb copolymers for regulating cell-surface interactions
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
EP1459757A1 (en) 1999-04-02 2004-09-22 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
WO2000059515A2 (en) 1999-04-02 2000-10-12 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
JP2001055335A (ja) 1999-08-18 2001-02-27 Toshio Sato アレルギー性皮膚疾患治療剤
US6995237B1 (en) 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
JPWO2002055091A1 (ja) 2001-01-12 2004-05-13 天藤製薬株式会社 抗アレルギー剤
EP1494687A2 (en) 2002-03-08 2005-01-12 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
AU2003218144B2 (en) 2002-03-13 2008-08-14 The Brigham And Women's Hospital, Inc. Method for overexpression of zwitterionic polysaccharides
EP1638581A2 (en) 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis

Also Published As

Publication number Publication date
AU2002228890A1 (en) 2002-06-18
AR036984A1 (es) 2004-10-20
JP4431311B2 (ja) 2010-03-10
JP2004536028A (ja) 2004-12-02
US7629330B2 (en) 2009-12-08
CA2436666C (en) 2013-05-21
EP1365774A2 (en) 2003-12-03
WO2002045708A9 (en) 2003-11-06
US20090317410A1 (en) 2009-12-24
WO2002045708A2 (en) 2002-06-13
PE20020783A1 (es) 2002-09-05
US8008276B2 (en) 2011-08-30
JP2009102305A (ja) 2009-05-14
US20040092433A1 (en) 2004-05-13
WO2002045708A3 (en) 2003-09-04
CA2436666A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
SV2003000753A (es) Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
NZ533179A (en) Hydroxycucurbituril derivatives, their preparation methods and uses
DE602004020467D1 (de) Behälter mit einer bodenstruktur zur vakuumabsorption
AR047692A1 (es) Imagenes de blancos estacionarios
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
BR122018002908B8 (pt) espuma e artigo absorvente
BR112018015938A2 (pt) ?artigo absorvente?
AR028772A1 (es) 5-aminoalquil-pirazol[4,3-d] pirimidinas
PA8579301A1 (es) Derivados de tiazol
ATE485308T1 (de) Epimerderivate von k5-polysaccharid mit hohem sulfatierungsgrad
ATE366753T1 (de) Polymerisationsverfahren mit diacylperoxiden
AU302434S (en) Vibroheat capsule I
AR035988A1 (es) Derivados de pirrolo-(3,4-b)quinoleina, su procedimiento de preparacion y su uso para la preparacion de medicamento
PL1763343T3 (pl) Trifluorooctan sodu do wytwarzania leków antyangiogennych
DE60045663D1 (de) Rlichem interferon-alpha
PL356897A1 (en) High stability bacteriophage preparation and application of block copolymer of ethyl oxide and propylene oxide
UA27430U (en) Method for generating normotrophic cicatrix of upper lip
UY28091A1 (es) Derivados de indolilo
CN201949253U (zh) 一种医用防止足部褥疮的充气垫圈
DE602004024809D1 (de) Telechele emittierende oligomere und davon abgeleitete polymere
BR8302911U (pt) Massageador roll-on
AU151030S (en) Garden peg
IT1317481B1 (it) Apparecchiatura per rilevare le dimensioni dei pezzi da lavorare, inparticolare in macchine per la lavorazione del legno.
AU301662S (en) Baby bath stand
TH51234EX (th) โต๊ะ